Pibrentasvir


Catalog No. size PriceQuantity
M7091-2 2mg solid $123
M7091-10 10mg solid $476

Description

Pibrentasvir, also known as ABT-530, is a protease inhibitor potentially for the treatment of HCV infection.

Product information

CAS Number: 1353900-92-1

Molecular Weight: 1113.18

Formula: C57H65F5N10O8

Synonym:

ABT-530

A-1325912

A-1325912.0

Related CAS Number:

1821461-48-6 (butanamine hydrate)

Chemical Name: dimethyl((2S,2'S,3R,3'R)-((2S,2'S)-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-1H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate

Smiles: C[C@@H](OC)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1NC2=CC(F)=C(C=C2N=1)[C@H]1CC[C@H](C2C=C3N=C(NC3=CC=2F)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)N1C1C=C(F)C(=C(F)C=1)N1CCC(CC1)C1C=CC(F)=CC=1

InChiKey: VJYSBPDEJWLKKJ-NLIMODCCSA-N

InChi: InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

References:

  1. Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol. 2019 Jan;14:89-110. doi: 10.2217/fmb-2018-0233. Epub 2018 Nov 30. Review. PubMed PMID: 30499343.
  2. Clinical Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation): Indication: Hepatitis C genotype 1 to 6 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533768/ PubMed PMID: 30462453.
  3. Pharmacoeconomic Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation): Indication: Hepatitis C genotype 1 to 6 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533682/ PubMed PMID: 30462452.
  4. CADTH Canadian Drug Expert Committee Recommendation: Glecaprevir / Pibrentasvir (Maviret — Abbvie Corporation): Indication: Chronic hepatitis C virus infection [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533338/ PubMed PMID: 30457786.
  5. Glecaprevir/pibrentasvir for hepatitis C. Aust Prescr. 2018 Oct;41(5):169-170. doi: 10.18773/austprescr.2018.050. Epub 2018 Aug 2. Review. PubMed PMID: 30410216; PubMed Central PMCID: PMC6202291.

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed